Cargando…

Profile of olaparib in the treatment of advanced ovarian cancer

Olaparib is a poly(ADP-ribose) polymerase inhibitor that received accelerated approval from the US Food and Drug Administration as monotherapy for patients with germline BRCA mutations and ovarian cancer treated with three or more prior lines of chemotherapy. This article summarizes the mechanism of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chase, Dana M, Patel, Shreya, Shields, Kristin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4847603/ https://www.ncbi.nlm.nih.gov/pubmed/27186080 http://dx.doi.org/10.2147/IJWH.S55906

Ejemplares similares

Olaparib in the management of ovarian cancer
por: Bixel, Kristin, et al.
Publicado: (2015)

Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date
por: Montemorano, Lauren, et al.
Publicado: (2019)

Olaparib in Epithelial Ovarian Cancer
por: Anastasia, Paula J.
Publicado: (2016)

Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib
por: Shaw, Heather M, et al.
Publicado: (2013)

Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer
por: Ledermann, Jonathan A., et al.
Publicado: (2019)

Olaparib and advanced ovarian cancer: Summary of the past and looking into the future
por: Maiorano, Brigida Anna, et al.
Publicado: (2023)

Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy
por: Lorusso, Domenica, et al.
Publicado: (2018)

Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease
por: Bangham, Madeleine, et al.
Publicado: (2016)

Systematic Review of Olaparib in the Treatment of Recurrent Platinum Sensitive Ovarian Cancer
por: Chen, Qian, et al.
Publicado: (2022)

Olaparib-induced pseudoporphyria in a patient with ovarian cancer
por: Clark, Abigale, et al.
Publicado: (2023)

Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells
por: Burgess, Brian T., et al.
Publicado: (2020)

Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China
por: Ni, Jing, et al.
Publicado: (2019)

Pneumocystis Pneumonia in a Patient with Ovarian Cancer Receiving Olaparib Therapy
por: Himeji, Daisuke, et al.
Publicado: (2021)

Olaparib in an ovarian cancer patient with end-stage renal disease and hemodialysis
por: Baum, Joanna, et al.
Publicado: (2023)

Retrospective efficacy analysis of olaparib combined with bevacizumab in the treatment of advanced colorectal cancer
por: Jiang, Yi-Ling, et al.
Publicado: (2023)

Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol
por: Mansouri, Anita, et al.
Publicado: (2021)

Real‐world clinical outcomes of olaparib therapy in Chinese patients with advanced serous ovarian cancer treated in Macau
por: Cao, Yabing, et al.
Publicado: (2019)

A Phase I dose‐escalation study of two cycles carboplatin‐olaparib followed by olaparib monotherapy in patients with advanced cancer
por: Geenen, Jill J. J., et al.
Publicado: (2021)

Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)
por: Mahdi, Haider, et al.
Publicado: (2021)

MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer
por: Yi, Jingyan, et al.
Publicado: (2019)

Olaparib Treatment in a Patient with Advanced Gallbladder Cancer Harboring BRCA1 Mutation
por: Li, Xiaofen, et al.
Publicado: (2021)

Olaparib treatment in older patients with ovarian cancer: need for ‘real-world’ data beyond clinical trials
por: Liposits, Gabor, et al.
Publicado: (2020)

Combination treatment with cisplatin, paclitaxel and olaparib has synergistic and dose reduction potential in ovarian cancer cells
por: Gao, Jianwen, et al.
Publicado: (2021)

First-Line Treatment with Olaparib for Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research
por: Tomao, Federica, et al.
Publicado: (2020)

Feasibility Study of a Network Meta-Analysis and Unanchored Population-Adjusted Indirect Treatment Comparison of Niraparib, Olaparib, and Bevacizumab as Maintenance Therapies in Patients with Newly Diagnosed Advanced Ovarian Cancer
por: Lorusso, Domenica, et al.
Publicado: (2022)

Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer
por: Tang, Sangsang, et al.
Publicado: (2022)

Defective DNA repair mechanisms in prostate cancer: impact of olaparib
por: De Felice, Francesca, et al.
Publicado: (2017)

Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Brca1 Proficient and Deficient Murine Ovarian Cells
por: Chiappa, Michela, et al.
Publicado: (2022)

Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer
por: Yarchoan, Mark, et al.
Publicado: (2017)

Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer
por: Rafii, Saeed, et al.
Publicado: (2017)

Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
por: Elsea, David, et al.
Publicado: (2022)

Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer
por: Ledermann, Jonathan A, et al.
Publicado: (2016)

Evolutionary dynamics of cancer multidrug resistance in response to olaparib and photodynamic therapy
por: Baglo, Yan, et al.
Publicado: (2021)

Olaparib induced senescence under P16 or P53 dependent manner in ovarian cancer
por: Wang, Zehua, et al.
Publicado: (2018)

Metformin Affects Olaparib Sensitivity through Induction of Apoptosis in Epithelial Ovarian Cancer Cell Lines
por: Gralewska, Patrycja, et al.
Publicado: (2021)

Proguanil synergistically sensitizes ovarian cancer cells to olaparib by increasing DNA damage and inducing apoptosis
por: Wu, Yan, et al.
Publicado: (2022)

Inhibition of PKM2 Enhances Sensitivity of Olaparib to Ovarian Cancer Cells and Induces DNA Damage
por: Zhou, Sichun, et al.
Publicado: (2022)

Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer
por: Zhong, Lixian, et al.
Publicado: (2018)

Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response
por: Franzese, Elisena, et al.
Publicado: (2019)

Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States
por: Guy, Holly, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_a1agbqt5h30976rutn8gpvu5o3